AACR Conference Coverage
Featured Articles
(Johns Hopkins Medicine) Apr 3, 2019 - Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention. It used to be when you were diagnosed with metastatic cancer, you were told to get your...
Read Article
(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four...
Read Article
Latest Articles
April 05, 2019
April 04, 2019
April 04, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
April 03, 2019
View More
News Commentary
Editor Image
03 Apr, 2019 | by H. Jack West, MD
Nice to see further long-term survival data, really in keeping with what we've...
View Comment
Editor Image
02 Apr, 2019 | by Tomasz M. Beer, MD
A badly misleading title. This study could not determine if survival is...
View Comment
View More
Featured Videos
There are no videos.
OBR Blog
Facts first, then comments. Keynote -189: This phase III trial compared pembrolizumab (pembro), or placebo, plus... Read more
April 17, 2018
A pre-meeting webinar provided a glimpse of some of the key presentations at the upcoming annual meeting of the... Read more
March 16, 2018

OBR Tweets

May 26
H. Jack West, MD: Another option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib… https://t.co/k9fEkGefkq

May 26
H. Jack West, MD: Elderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse eff… https://t.co/qvJRVE5FyX

May 22
A recent FDA workshop delved into liquid biopsy screening approaches as they are increasingly being applied, partic… https://t.co/ZC83sOvoO2

May 21
H. Jack West, MD: While it's always nice to have another option, it's hard for me to see how atezolizumab provides… https://t.co/TUgQMgLwcA

May 21
Tomasz M. Beer, MD: PAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patien… https://t.co/V0TnoRIDfR

May 20
At the #aacr2020 Virtual Meeting I, there was pivotal data from immunotherapy triplet trials in breast cancer, mela… https://t.co/eJ1m97OA6G

May 20
The emergence of #COVID-19 has transformed the care of cancer patients and upended the way practices do business. D… https://t.co/yLcc5dTpjn

May 19
At @oncologyCOA's first virtual conference, presenters discussed modernizing the clinical trial process, the comple… https://t.co/VIBVh1b8bA

May 19
Join us Tonight, May 19th 7:30 ET for a webinar discussing the unique management of advanced hepatocellular carcino… https://t.co/lgdd4xzlDb

May 19
H. Jack West, MD: I imagine that the nivolumab/ipilumumab combination will have some appeal to patients or physicia… https://t.co/faXlyOvMeC